Abstract

BackgroundCancer has become one of the main causes of death globally. The level of tumor markers in serum is correlated with the occurrence of cancer. Carcinoembryonic antigen (CEA) is the most commonly utilized tumor marker for cancer detection. Recently, various analytical technologies have been reported to detect biomarkers. However, developing a simple, sensitive, and noninvasive approach for CEA detection remains challenging in cancer diagnosis. Consequently, there is an urgent need for researchers to carry out innovative approaches for CEA detection. ResultIn this work, copper ferrite nanoparticles (CuFe2O4 NPs) with excellent dispersity and fascinating magnetism have been successfully synthesized. To get CuFe2O4@ABEI-GNPs, ABEI-gold NPs (ABEI-GNPs) were generated on the surface of CuFe2O4 NPs by using N-(4-Aminobutyl)-N-ethylisoluminol (ABEI) as a mild reduction reagent to reduce chloroauric acid tetrahydrate (HAuCl4·4H2O). The CuFe2O4@ABEI-GNPs exhibited a superior chemiluminescence (CL) performance compared with CuFe2O4@ABEI NPs, which was attributed to the synergistic catalysis effects of CuFe2O4 NPs and GNPs. Interestingly, two unique CL emission peaks were observed in the kinetic curve of CuFe2O4@ABEI-GNPs. Furthermore, it was found that the kinetic curve could be regulated by the pH of hydrogen peroxide (H2O2) and a possible CL mechanism was proposed. Owing to the favorable CL properties of CuFe2O4@ABEI-GNPs, a label-free differential immunosensor was fabricated for CEA monitoring using the intensity difference between CL-1 and CL-2. The developed immunosensor exhibited a wide linear range from 0.1 to 5000 pg/mL, and a low detection limit of 0.05 pg/mL. Significance and noveltyThe immunosensor was capable of determining CEA in real samples with simple operation, high accuracy, and good sensitivity. This study introduces a novel approach for developing CL functionalized materials, which have broad application potential in bioassays. The proposed differential method could serve as a novel tool for determining CEA in the diagnosis of clinical cancer.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.